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Abstract
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic 
stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate 
metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as 
compared to those who are CYP3A5 non-expressers (poor metabolizers), possibly delaying 
achievement of target blood concentrations. We summarize evidence from the published literature 
supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 
genotype when known (updates at www.pharmgkb.org).
Corresponding author: Kelly Birdwell, MD, MSCI, Assistant Professor of Medicine, Vanderbilt University Medical Center, 
Division of Nephrology and Hypertension, S-3223 MCN, Nashville, TN 37232-2372, Phone: 615.322.6976, 
kelly.birdwell@vanderbilt.edu. 
Conflict of Interest
All other authors declare no conflicts.
HHS Public Access
Author manuscript
Clin Pharmacol Ther. Author manuscript; available in PMC 2015 July 01.
Published in final edited form as:
Clin Pharmacol Ther. 2015 July ; 98(1): 19–24. doi:10.1002/cpt.113.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Keywords
Tacrolimus; CYP3A5; immunosuppressant; pharmacogenetics; pharmacogenomics; transplant
Introduction
Tacrolimus is a widely used immunosuppressive medication with a narrow therapeutic index 
and large between-patient pharmacokinetic variability, which is partly due to genetic 
variations in CYP3A5. The purpose of this guideline is to provide information relevant to the 
interpretation of CYP3A5 genotype results to guide dosing of tacrolimus. Detailed guidelines 
for use of tacrolimus as well as analyses of cost effectiveness are not discussed. CPIC 
guidelines are periodically updated at http://www.pharmgkb.org.
Focused Literature Review
A systematic literature review focused on CYP3A5 genotype and tacrolimus use (see 
Supplemental Material online) was conducted.
Gene: CYP3A5
Background
Enzymes in the cytochrome P450 (CYP) 3A family are responsible for the oxidative 
metabolism of tacrolimus. Four genes in this family have been described, but only CYP3A4 
and CYP3A5 are thought to be relevant in adults. CYP3A7 is only expressed in fetal liver 
and CYP3A43 is of uncertain significance. There is a high degree of sequence homology 
between CYP3A4 and CYP3A5 and thus substrate overlap (1). Both first pass metabolism 
and systemic clearance of drugs metabolized by CYP3A5 are susceptible to genetically 
determined differences in enzyme expression. Variant alleles for CYP3A5 (*3, *6, or *7) 
may result in truncated mRNA with loss of expression of the functional protein in 
homozygotes or compound heterozygotes, or encode non-functional protein (2). The 
physiological function of CYP3A5 is unclear. Whereas CYP3A4 poor metabolizers are rare, 
absence of functional CYP3A5 is the norm in many populations. This is most notable for 
Caucasians with 80–85% of the population being homozygous for the variant CYP3A5*3 
allele (3). It appears that retention of CYP3A5 expression has been under some evolutionary 
selection pressure in populations originating close to the equator and loss of this positive 
selection pressure with migration away from the equator, possibly related to the benefits 
derived from a sodium retaining phenotype in hot climates (4).
Genetic Test Interpretation
Each named * allele is defined by the genotype at one or more specific SNPs (Supplemental 
Table S1). The function associated with these allelic variants is summarized in Supplemental 
Table S2. The assignment of the likely CYP3A5 phenotype, based on * allele diplotypes, is 
summarized in Table 1. CYP3A5 alleles have been extensively studied in groups with 
diverse geographical ancestries (Supplemental Table S3). One of the limitations inherent in 
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a genotype-only test is that rare or de novo variants may not be included in commercially 
available genotyping tests.
Available Genetic Test Options
See Supplementary material and www.PharmGKB.org for more information on 
commercially available clinical testing options.
Incidental findings
No clear diseases or conditions have been linked to variation in CYP3A5 unrelated to 
medication use.
Other considerations
Most genetic tests examine the presence of the CYP3A5 *3 allele. Less commonly observed 
and possibly not included, depending on the assay, are CYP3A5*6 and CYP3A5*7 alleles, 
which are associated with decreased CYP3A5 activity, similar to that observed for 
CYP3A5*3. Additional rare variants such as *2, *8, *9 may be found which are of unknown 
functional significance.
In this guideline, we use phenotype nomenclature consistent with other CYP enzymes (i.e. 
extensive metabolizer, intermediate metabolizer and poor metabolizer). Typically with other 
CYP enzymes, an extensive metabolizer would be classified as a “normal” metabolizer, and 
therefore, the drug dose would not change based on the patient’s genotype. However, in the 
case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e. CYP3A5 extensive metabolizer 
or intermediate metabolizer) would require a higher recommended starting dose and the 
CYP3A5 non-expresser (i.e. poor metabolizer) would require the standard recommended 
starting dose. CYP3A5 expressers constitute the minority in European populations. 
Additional clinician education might be necessary to avoid confusion.
Drug: Tacrolimus
Background
Tacrolimus was approved in 1994 by the FDA as an antirejection medication for liver 
transplantation. Tacrolimus is a macrolide that binds to its cytoplasmic protein receptor, FK 
binding protein 12 (FKBP-12), in T-lymphocytes. This complex binds calcineurin, 
preventing dephosphorylation and nuclear translocation of nuclear factor of activated T-
cells, ultimately inhibiting IL-2 production and T-lymphocyte activation (5). Today, 
tacrolimus is one of the most widely prescribed immunosuppressive medications in solid 
organ transplantation and is also increasingly being used in the treatment of 
glomerulonephritis and graft versus host disease (GVHD). Tacrolimus in clinical use is 
complicated by its high between-patient variability in pharmacokinetics as well as its narrow 
therapeutic index. This may lead to underexposure, potentially increasing the risk of 
rejection, or overexposure, with risk of toxicity including nephrotoxicity, hypertension, 
neurotoxicity, and hyperglycemia (6). As a result, current management of tacrolimus usually 
includes therapeutic drug monitoring (TDM) (7). Clinically, TDM is done using using 
tacrolimus whole blood trough concentrations which have been shown to correlate with area 
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under the curve measurements (8, 9). Previous studies have shown a relationship between 
lower tacrolimus exposure and acute rejection and higher exposure and toxicities (see 
Supplemental Table S4). The addition of induction therapies and mycophenolate has 
allowed lower target trough levels, as exemplified by the Symphony study in kidney 
transplant, in which patients randomized to low dose tacrolimus with target levels of 3–
7ng/mL had less rejection and better kidney function (10). Though TDM is helpful for 
adjusting subsequent doses based on blood concentrations, it provides no information for the 
initial dose. Individual differences in first pass metabolism (see below) may delay reaching 
target blood concentrations with the initial selected dose. Furthermore, although achieving 
target blood concentrations does not always ensure efficacy or diminish adverse events, 
target blood concentrations specific for organ type and time post-transplant are available in 
the package insert and established by consensus guidelines (7, 11).
Demethylation and hydroxylation of tacrolimus occurs by hepatic and intestinal CYP3A 
isoforms (CYP3A4and CYP3A5). Tacrolimus is also a substrate for the multidrug efflux 
transporter P-glycoprotein (encoded by the ABCB1 gene, previously called MDR1), which is 
expressed on various epithelial and endothelial cells and lymphocytes. First pass metabolism 
by CYP3A4 and CYP3A5 in the intestine and liver contributes to the poor oral 
bioavailability of tacrolimus which is only around 20%. Tacrolimus is cleared through 
hepatic metabolism by CYP3A4 and CYP3A5 with biliary excretion of metabolites.
Linking genetic variability to variability in drug-related phenotypes
Blood concentrations of tacrolimus are strongly influenced by CYP3A5 genotype, 
withsubstantial evidence linking CYP3A5 genotype with phenotypic variability (see 
Supplemental Table S4). The application of a grading system to the evidence linking 
genotypic to phenotypic variability indicates a high quality of evidence in the majority of 
cases (see Supplemental Table S4). The evidence described below and in Supplementary 
Table S4 provides the basis for the dosing recommendations in Table 2.
In kidney, heart and lung transplant patients, over 50 studies have found that individuals 
with the CYP3A5*1/*1 or CYP3A5*1/*3 genotype have significantly lower dose-adjusted 
trough concentrations of tacrolimus as compared to those with the CYP3A5*3/*3 genotype, 
with *1 carriers requiring 1.5 to 2 times the dose to achieve similar blood concentration 
levels (see Supplemental Table S4). CYP3A5*1/*3 is believed to explain up to 45% of the 
variability in tacrolimus dose (12). Due to the rarity of the CYP3A5*6 and CYP3A5*7 alleles 
in most populations (see Supplemental Table S3), their impact on tacrolimus dose-adjusted 
trough concentrations has only been examined in combined analyses with CYP3A5*3 (13, 
14). However, since both alleles result in a non-functional protein (13), their impact on 
tacrolimus clearance and dose-adjusted trough concentrations is presumed to be identical to 
CYP3A5*3.
Therapeutic Recommendations
This guideline is not intended to recommend for or against CYP3A5 genotype testing in 
transplant. The current evidence for utility of CYP3A5 genotyping to guide tacrolimus 
dosing is limited to CYP3A5’s effect on tacrolimus pharmacokinetic parameters, with no 
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direct evidence for improved clinical immunosuppressant outcome. As a result, we are not 
recommending whether or not to test for CYP3A5 genotype in transplant, but we are 
providing recommendations on how to use CYP3A5 genotype information if it is known. 
Since it is typical clinical practice to achieve target blood concentrations as quickly as 
possible, we do recommend if CYP3A5 genotype is known, to individualize initial 
tacrolimus treatment using CYP3A5 genotype to guide tacrolimus dosing as outlined in 
Table 2. Transplant recipients with the poor metabolizer phenotype (Table 1) should receive 
the standard dosing of medication based on the tacrolimus package insert. Those recipients 
with an extensive or intermediate metabolizer phenotype will generally require an increased 
dose of tacrolimus to achieve therapeutic drug concentrations. We recommend a dose 1.5–2 
times higher than standard dosing, but not to exceed 0.3 mg/kg/day, followed by TDM given 
the risk of arterial vasoconstriction, hypertension and nephrotoxicity that can occur with 
supratherapeutic tacrolimus concentrations (15, 16). In addition, concomitant medications, 
abnormal liver function or presence of clinical conditions such as diarrhea must be taken 
into consideration when dosing tacrolimus (see Other Considerations below).
Given the availability of TDM, genetic testing is most helpful prior to initiation of the drug 
in order to more rapidly achieve therapeutic drug concentrations. This was illustrated in a 
randomized controlled trial by Thervet et al. where target tacrolimus blood concentrations 
were achieved earlier in new kidney transplant recipients whose tacrolimus dose was chosen 
based on CYP3A5 genotype versus a control group that started tacrolimus based on standard 
weight-based dosing. In this study, patients received induction therapy with either 
basiliximab or antithymocyte globulin. Extensive metabolizers in the genotyped- dosed 
group had an increase in tacrolimus dose to 0.3 mg/kg/day whereas the poor metabolizers 
had a decrease to 0.15 mg/kg/day, and the control group received 0.2 mg/kg/day. 
Therapeutic drug monitoring was used in both groups. At 3 days after starting treatment with 
tacrolimus, significantly more of the transplant recipients in the genotyping group compared 
to control recipients had achieved target range (43.2% versus 29.1%, respectively) (17). 
However, it should be noted that tacrolimus was not started until day 7 while awaiting 
genotyping test results, which may differ from standard treatments with a start of tacrolimus 
at the time of transplantation. No differences were seen in patient survival, nephrotoxicity, 
or acute rejection between the groups over the 3 month follow-up. With this study as the 
only published randomized control trial, more data are needed to understand if dosing 
tacrolimus by genotype will affect clinical outcomes. However, a recent meta-analysis 
including 21 studies evaluating the effect of CYP3A5 polymorphism on kidney transplant 
recipients concluded that there is a significantly increased risk for transplant rejection for 
those with the CYP3A5*1/*1 or CYP3A5*1/*3 genotype (p=0.04, OR=1.32). Furthermore, 
patients with the CYP3A5*3/*3 (non expresser) genotype exhibited a dose-adjusted trough 
concentrations 1.8 to 2.5 times higher than CYP3A5 expressers during the first year after 
transplantation (18).
Thus at present, there is no definitive evidence to indicate that genotype-guided dosing for 
tacrolimus affects long term clinical outcomes. However there is strong evidence to support 
its effect on achieving target trough whole blood concentrations, which is routine clinical 
practice for most centers (see Supplemental Table S4). Besides initial dose, genotype-guided 
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dosing may be also useful in patients in whom achieving therapeutic blood concentrations 
has been difficult, where genotype may provide some additional information to discern the 
reason.
In liver transplant patients, the CYP3A5 genotype of the donor liver may not be the same as 
the CYP3A5 genotype of the recipient intestine. In these cases, it may be necessary to 
account for both the donor and recipient genotypes when determining the dose. However, 
studies to date have been inconclusive as to the relative influence of the donor and recipient 
genotypes, and whether donor liver and recipient intestinal genotypes come into play at 
different points post-transplant. While some studies show that the donor genotype affects 
dose-adjusted trough concentrations from the first week post-transplant (19, 20), others 
show that it does not begin to play a role until the second week or even the sixth month post-
transplant (21–23). Evidence is also conflicting for recipient intestinal genotype: a few 
studies show that it never significantly affects tacrolimus concentrations (20, 22, 23), 
whereas others show its influence on concentrations is only significant up to the point at 
which donor genotype becomes significant (21, 24). Due to the small number of studies 
analyzing these cases, as well as inconsistent results, this guideline recommendation only 
includes kidney, heart, lung and hematopoietic stem cell transplant patients, and liver 
transplant patients where the donor and recipient genotypes are identical.
Pediatrics
The effect of CYP3A5 genotype on dose-corrected tacrolimus concentration in pediatric 
populations has been studied in several clinical settings, including heart (25, 26) and liver 
transplantation (27), but most extensively following kidney transplantation (28–33). 
Unfortunately, available data vary in terms of study duration following transplant and 
inclusion of additional factors that impact the dose-exposure relationship. In general, 
although the dose-exposure relationship changes over time regardless of genotype, dose-
corrected tacrolimus trough concentrations are 1.5- to 2-fold higher in kidney transplant 
patients with CYP3A5*3/*3 genotypes compared to patients with CYP3A5*1/*1 or *1/*3 
genotypes over the first two (31) to four (29) weeks post-transplant, at 6 months (32), and 
throughout the first year post-transplant (28, 30, 33). However, patient age and concurrent 
drug therapy also contribute to variability in the tacrolimus dose-exposure relationship in 
children. For example, post-pubertal renal transplant patients (age >12 years) have higher 
dose-corrected tacrolimus concentrations compared to younger children in the first 2–3 
weeks post-transplantation period (31, 34) or over the first year post-transplant (30, 33, 34), 
indicative of a lower dose requirement to achieve a comparable target concentration (33). 
Thus, for children and adolescents with at least one CYP3A5*1 allele, a 1.5- to 2-fold 
increase in dose followed by TDM as recommended for adults appears appropriate.
The Supplementary Material online contains example clinical decision support (CDS) tools 
that can be used within electronic health records (EHRs) which assist clinicians to use 
genetic information to optimize drug therapy. Clinical implementation resources include 
cross-references for drug and gene names to widely used terminologies and standardized 
nomenclature systems (Supplementary Tables S5 and S6 online), workflow diagrams 
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(Supplementary Figures S1 and S2 online), and example text for documentation in the EHR 
and point-of care alerts (Supplementary Tables S7 and S8 online).
Recommendations for Incidental Findings
Not applicable.
Other considerations
Several drugs (drug-drug interactions) are important to consider, especially 
nondihydropyridine calcium channel blockers and azole anti-fungals that are commonly co-
administered in the transplant population. The drug interaction with the azole anti-fungals 
has been reported to be less profound in CYP3A5 expressers (35, 36). For additional 
information on tacrolimus drug interactions, see the review by van Gelder (37). Specific 
patient factors such as fasting or diarrhea may cause altered absorption that can affect 
tacrolimus concentrations. This has been extensively reviewed in an article by Staatz et al 
(38).
Additional genetic variants described in the literature but with unclear effects on tacrolimus 
metabolism due to either limited or conflicting studies include CYP3A4*22, POR*28, PPAR 
alpha, and ABCB1. A critical issue in predicting tacrolimus clearance in vivo is the relative 
contribution of CYP3A4 compared to CYP3A5 to its metabolism. Because of the complete 
loss of metabolic activity with the CYP3A5*3 allele, the impact of variation in CYP3A4 may 
be high in those with no CYP3A5 expression. Of note, donor CYP3A5 genotype may play a 
role in pharmacodynamics. In kidney transplant recipients, the CYP3A5 genotype, together 
with the donor ABCB1 genotype may affect the susceptibility of the kidney for tacrolimus 
nephrotoxicity (39). While the current guideline refers to using recipient CYP3A5 genotype 
to guide selection of the optimal initial dose for tacrolimus, we can expect the potential for 
greater predictive value in polygenic algorithms.
A further confounding factor is the influence of ethnicity. While it was initially 
hypothesized that individuals of African origin require high doses of tacrolimus because of 
expression of CYP3A5, these individuals have high dose requirement for tacrolimus, 
irrespective of CYP3A5 genotype (40). This finding suggests other factors besides CYP3A5 
genotype are important in individuals of sub Saharan African descent.
Potential Benefits and Risks for the Patient
Tacrolimus dosing is routinely directed by TDM. Yet, for patients who have an existing 
CYP3A5 genotyping result, CYP3A5 genotype guided dosing can achieve initial target 
tacrolimus concentrations more quickly after transplantation even when TDM based titration 
is used (17). Faster achievement of target concentrations could potentially reduce the risk of 
graft-rejection due to under-exposure and toxicity due to over-exposure. However, 
prospective clinical trials are needed to assess if CYP3A5 genotype guided dosing improves 
these outcomes.
CYP3A5 genotyping cannot replace therapeutic drug monitoring, as other factors (i.e. 
demographic factors, drug–drug interactions, genetic variation affecting tacrolimus 
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pharmacodynamics) also influence tacrolimus dose requirements. As with any genetic test a 
possible risk is the misreporting or misinterpretation of genotype test results. An error in 
genotyping could result in an increase in tacrolimus dose and subsequently over-exposure. 
However, anticipated effects are limited due to stringent TDM.
Caveats: Appropriate Use and/or Potential Misuse of Genetic Tests
Dose alterations based on CYP3A5 genotype may result in faster achievement of target 
tacrolimus concentrations with fewer dose adjustments (17). In addition, several clinical 
caveats apply: 1) clinical factors (e.g., age, concomitant drugs) affect tacrolimus 
concentrations; 2) variants in genes other than CYP3A5 may affect tacrolimus 
pharmacokinetics and therefore overall exposure; 3) the relationship between tacrolimus 
concentration and efficacy and toxicity varies among individuals (pharmacodynamic 
variability); 4) the genetic determinants of tacrolimus efficacy and toxicity 
(pharmacodynamics) are not defined; 5) altering initial tacrolimus dosing based on CYP3A5 
genotype has not been shown to improve efficacy or reduce toxicity; and 6) monitoring of 
tacrolimus blood concentration remains indicated during treatment. With the expansion of 
our knowledge base, further refinement of the genotype-based dosing recommendations may 
be required.
Disclaimer
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert 
consensus based on clinical evidence and peer-reviewed literature available at the time they 
are written, and are intended only to assist clinicians in decision-making, as well as to 
identify questions for further research. New evidence may have emerged since the time a 
guideline was submitted for publication. Guidelines are limited in scope and are not 
applicable to interventions or diseases not specifically identified. Guidelines do not account 
for all individual variation among patients and cannot be considered inclusive of all proper 
methods of care or exclusive of other treatments. It remains the responsibility of the health 
care provider to determine the best course of treatment for the patient. Adherence to any 
guideline is voluntary, with the ultimate determination regarding its application to be solely 
made by the clinician and the patient. CPIC assumes no responsibility for any injury to 
persons or damage to property related to any use of CPIC's guidelines, or for any errors or 
omissions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Assignment of likely metabolism phenotypes based on CYP3A5 diplotypes
Likely phenotype Genotypes Examples of diplotypes*
Extensive metabolizer (CYP3A5 
expresser)
An individual carrying two functional alleles *1/*1
Intermediate metabolizer (CYP3A5 
expresser)
An individual carrying one functional allele and one 
non-functional allele
*1/*3, *1/*6, *1/*7
Poor metabolizer (CYP3A5 non-
expresser)
An individual carrying two non-functional alleles *3/*3, *6/*6, *7/*7, *3/*6, *3/*7, *6/*7
*Additional rare variants such as CYP3A5*2, *8, and *9 may be found which are of unknown functional significance. However, if a copy of *1 is 
present, expected phenotype would be intermediate metabolizer.
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Table 2
Dosing recommendations for tacrolimus based on CYP3A5 phenotype
CYP3A5 phenotypea Implications for tacrolimus
pharmacologic measures
Therapeutic
recommendationsb
Classification of
Recommendationsd
Extensive Metabolizer 
(CYP3A5 expresser)
Lower dose-adjusted trough 
concentrations of tacrolimus and 
decreased chance of achieving 
target tacrolimus concentrations.
Increase starting dose 1.5 to 2 times 
recommended starting dosec. Total starting dose 
should not exceed 0.3mg/kg/day. Use 
therapeutic drug monitoring to guide dose 
adjustments.
Strong
Intermediate Metabolizer 
(CYP3A5 expresser)
Lower dose-adjusted trough 
concentrations of tacrolimus and 
decreased chance of achieving 
target tacrolimus concentrations.
Increase starting dose 1.5 to 2 times 
recommended starting dosea. Total starting 
dose should not exceed 0.3mg/kg/day. Use 
therapeutic drug monitoring to guide dose 
adjustments.
Strong
Poor Metabolizer 
(CYP3A5 non-expresser)
Higher (“normal”) dose-adjusted 
trough concentrations of tacrolimus 
and increased chance of achieving 
target tacrolimus concentrations.
Initiate therapy with standard recommended 
dose. Use therapeutic drug monitoring to guide 
dose adjustments.
Strong
a
Typically with other CYP enzymes, an extensive metabolizer would be classified as a “normal” metabolizer, and therefore, the drug dose would 
not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e. CYP3A5 extensive 
metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e. poor metabolizer) 
would require the standard recommended starting dose.
b
This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant 
patients where the donor and recipient genotypes are identical.
c
Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic 
function)
d
Rating scheme is described in Supplementary Data online.
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